Диссертация (1139747), страница 26
Текст из файла (страница 26)
XVI, Issue 2/2011, 182-18789.Minden K. Adult outcomes of patients with juvenile idiopathic arthritis.// Horm Res. 2009 Nov;72 Suppl 1:20-5. doi: 10.1159/000229759. Epub 2009Nov 2790.Miyamae T, Yokoya S, Yamanaka H, Yokota S. Effect of tocilizumabon growth impairment in systemic juvenile idiopathic arthritis with long-termcorticosteroid therapy. // Mod Rheumatol.
2014 Jul;24(4):567-71. doi:10.3109/14397595.2013.844404. Epub 2013 Oct 2191.Mondal R, Sarkar S, Das NK, Chakravorti S, Hazra A, Sabui T, NandiM, Ray B, Das A, Ganguli S, Growth of children with juvenile idiopathicarthritis. // Indian Pediatr. 2014 Mar;51(3):199-20292.Mrážik P., Košková E., Vargová V. Efficacy of TNF blockers from theperspective of growth velocity: slovak experience // Pediatr. Rheumatol.2014. Vol. 12.
Suppl 1. P. S14814993.Murakami M., Tomiita M., N. Nishimoto Tocilizumab in the treatmentof systemic juvenile idiopathic arthritis // Open Access Rheumatology:Research and Reviews 2012:4 71–7994.Okumus O, Erguven M, Deveci M, Yilmaz O, Okumus M. Growth andbone mineralization in patients with juvenile idiopathic arthritis. // Indian JPediatr.
2008 Mar;75(3):239-4395.Ostring GT, Singh-Grewal D. Juvenile idiopathic arthritis in the newworld of biologics. //J Paediatr Child Health. 2013 Sep;49(9):E405-12. doi:10.1111/jpc.12218. Epub 2013 May 696.Otten MH, Anink J, Spronk S, van Suijlekom-Smit LW, Efficacy ofbiological agents in juvenile idiopathic arthritis: a systematic review usingindirect comparisons.
//Ann Rheum Dis. 2013 Nov;72(11):1806-12. doi:10.1136/annrheumdis-2012-201991. Epub 2012 Nov 2197.Padeh S, Pinhas-Hamiel O, Zimmermann-Sloutskis D, Berkun Y.Children with oligoarticular juvenile idiopathic arthritis are at considerablerisk for growth retardation. // J Pediatr. 2011 Nov;159(5):832-837.e1-2. doi:10.1016/j.jpeds.2011.04.012.
Epub 2011 May 3198.Pietrewicz E, Urban M, Górska A. Cytokine levels in serum of patientswith juvenile idiopathic arthritis depending on subtype and disease activity. //Pol Merkur Lekarski. 2004 Sep;17(99):232-499.Polito C, Strano CG, Olivieri AN, Alessio M, Iammarrone CS, TodiscoN, Papale MR. Growth retardation in non-steroid treated juvenile rheumatoidarthritis. // Scand J Rheumatol. 1997;26(2):99-103100. Reiff A. Treatment of Systemic Juvenile Idiopathic Arthritis withTocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade ofTreatment. // Biol Ther.
2012 Feb 1;2:1. eCollection 2012101. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA,Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, SaadMagalhães C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M,Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L,150Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, GianniniEH; Paediatric Rheumatology INternational Trials Organization; PediatricRheumatology Collaborative Study Group, Abatacept in children withjuvenile idiopathic arthritis: a randomised, double-blind, placebo-controlledwithdrawaltrial//Lancet.2008Aug2;372(9636):383-91.doi:10.1016/S0140-6736(08)60998-8. Epub 2008 Jul 14.102. Ruperto N., Lovell D. J., Jarosova K., Nemcova V. The impact ofadalimumab on growth in patients with juvenile idiopathic arthritis // Pediatr.Rheumatol.
2013. Vol. 11. Suppl 2. P. SO4103. Rusconi R, Corona F, Grassi A, Carnelli V. Age at menarche in juvenilerheumatoid arthritis. // J Pediatr Endocrinol Metab. 2003 Mar;16 Suppl 2:2858.104. Russo R.A., Katsicas M.M. Patients with very early-onset systemicjuvenile idiopathic arthritis exhibit more inflammatory features and a worseoutcome // JRheumatol. 2013;40(3):329-34105. Schiappapietra B, Varnier G, Rosina S, Consolaro A, Martini A, RavelliA.Glucocorticoidsinjuvenileidiopathicarthritis.//Neuroimmunomodulation.
2015;22(1-2):112-8. doi: 10.1159/000362732.Epub 2014 Sep 12106. Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, HorneffG. Efficacy and safety of adalimumab as the first and second biologic agentin juvenile idiopathic arthritis: the German Biologics JIA Registry. // ArthritisRheumatol.
2014 Sep;66(9):2580-9. doi: 10.1002/art.38741107. Schmeling H, Seliger E, Horneff G. Growth reconstitution in juvenileidiopathic arthritis treated with etanercept. // Clin Exp Rheumatol. 2003 NovDec;21(6):779-84108. Sederquist B, Fernandez-Vojvodich P, Zaman F, Sävendahl L. Recentresearch on the growth plate: Impact of inflammatory cytokines onlongitudinal bone growth. // J Mol Endocrinol.
2014 Aug;53(1):T35-44. doi:10.1530/JME-14-0006. Epub 2014 Apr 7151109. Shenoi S, Wallace CA. Tumor necrosis factor inhibitors in themanagement of juvenile idiopathic arthritis: an evidence-based review. //Paediatr Drugs. 2010 Dec 1;12(6):367-77. doi: 10.2165/11532610000000000-00000110. Shiff NJ, Brant R, Guzman J, Cabral DA, Huber AM, Miettunen P,Roth J, Scuccimarri R, Alos N, Atkinson SA, Collet JP, Couch R, CummingsEA, Dent PB, Ellsworth J, Hay J, Houghton K, Jurencak R, Lang B, LarcheM, Leblanc C, Rodd C, Saint-Cyr C, Stein R, Stephure D, Taback S, RauchF, Ward LM; Canadian Steroid-associated Osteoporosis in the PediatricPopulation Consortium. Glucocorticoid-related changes in body mass indexamong children and adolescents with rheumatic diseases.
// Arthritis Care Res(Hoboken). 2013 Jan;65(1):113-21. doi: 10.1002/acr.21785111. Simon D, Fernando C, Czernichow P, Prieur AM. Linear growth andfinal height in patients with systemic juvenile idiopathic arthritis treated withlongterm glucocorticoids. // J Rheumatol. 2002 Jun;29(6):1296-300112. Simon D, Lucidarme N, Prieur AM, Ruiz JC, Czernichow P. Lineargrowth in children suffering from juvenile idiopathic arthritis requiringsteroid therapy: natural history and effects of growth hormone treatment onlinear growth. // J Pediatr Endocrinol Metab.
2001;14 Suppl 6:1483-6113. Simon D, Lucidarme N, Prieur AM, Ruiz JC, Czernichow P. Treatmentof growth failure in juvenile chronic arthritis. // Horm Res. 2002;58 Suppl1:28-32114. Simon D. Management of growth retardation in juvenile idiopathicarthritis. // Horm Res. 2007;68 Suppl 5:122-5. doi: 10.1159/000110605. Epub2007 Dec 10.115. Souza LS, Machado SH, Brenol CV, Brenol JC, Xavier RM.
Growthvelocity and interleukin 6 concentrations in juvenile idiopathic arthritis. // JRheumatol. 2008 Nov;35(11):2265-71. Epub 2008 Oct 1116. Spîrchez M, Samaşca G, Iancu M, Bolba C, Miu N. Relation ofinterleukin-6, TNF-alpha and interleukin-1 alpha with disease activity and152severity in juvenile idiopathic arthritis patients. // Clin Lab.
2012;58(3-4):25360117. Stoll ML, Cron RQ, Treatment of juvenile idiopathic arthritis: arevolution in care. //Pediatr Rheumatol Online J. 2014 Apr 23;12:13. doi:10.1186/1546-0096-12-13118. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis in thebiologic age. // Rheum Dis Clin North Am. 2013 Nov;39(4):751-66. doi:10.1016/j.rdc.2013.05.004. Epub 2013 Jul 5119.
Takahi K, Hashimoto J, Hayashida K, Shi K, Takano H, Tsuboi H,Matsui Y, Nakase T, Tomita T, Ochi T, Yoshikawa H. Early closure of growthplate causes poor growth of long bones in collagen-induced arthritis rats. JMusculoskelet Neuronal Interact. 2002 Jun;2(4):344-51120. Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidenceof juvenile idiopathic arthritis: a systematic review.
// Joint Bone Spine. 2014Mar;81(2):112-7. doi: 10.1016/j.jbspin.2013.09.003. Epub 2013 Nov 6121. Trachana M, P Triantafyllou, A Vraka, et.all / The impact of a 2-yearEtanercept administration on growth of patients with juvenile idiopathicarthritis // Pediatric Rheumatology 2011, 9(Suppl 1):P 149122. Tynjälä P, Lahdenne P, Vähäsalo P, Kautiainen H, Honkanen V. Impactof anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
// AnnRheum Dis. 2006 Aug;65(8):1044-9. Epub 2006 Jan 31123. Uettwiller F, Perlbarg J, Pinto G, Bader-Meunier B, Mouy R,Compeyrot-Lacassagne S, Melki I, Wouters C, Prieur AM, Landais P, PolakM, Quartier P. Effect of biologic treatments on growth in children withjuvenile idiopathic arthritis. // J Rheumatol. 2014 Jan;41(1):128-35. doi:10.3899/jrheum.130311. Epub 2013 Dec 1124. Umławska W, Krzyzanowska M. Growth and menarche duringremission in children with juvenile idiopathic arthritis. //Med Wieku Rozwoj.2009 Jul-Sep;13(3):194-200153125. Umławska W, Michałowska J, Podwysocka-Harasimowicz M. Physicaldevelopment in children with juvenile idiopathic arthritis. // PediatrEndocrinol Diabetes Metab.
2008;14(3):161-4126. Umławska W., Prusek-Dudkiewicz A. Growth retardation and delayedpuberty in children and adolescents with juvenile idiopathic arthritis / // ArchMed Sci 1, 2010: 19-23127. Ungar WJ, Costa V, Burnett HF, Feldman BM, Laxer RM. The use ofbiologic response modifiers in polyarticular-course juvenile idiopathicarthritis: a systematic review. // Semin Arthritis Rheum.
2013 Jun;42(6):597618. doi: 10.1016/j.semarthrit.2012.10.006. Epub 2013 Jan 18128. Valta H, Lahdenne P, Jalanko H, Aalto K, Mäkitie O. Bone health andgrowth in glucocorticoid-treated patients with juvenile idiopathic arthritis. //J Rheumatol. 2007 Apr;34(4):831-6. Epub 2007 Feb 15129. Vannucci G, Cantarini L, Giani T, Marrani E, Moretti D, Pagnini I,Simonini G, Cimaz R. Glucocorticoids in the management of systemicjuvenile idiopathic arthritis. // Paediatr Drugs. 2013 Oct;15(5):343-9.
doi:10.1007/s40272-013-0038-0130. Vastert SJ, Kuis W, Grom AA Systemic JIA: new developments in theunderstanding of the pathophysiology and therapy. //Best Pract Res ClinRheumatol. 2009 Oct;23(5):655-64. doi: 10.1016/j.berh.2009.08.003131. Vojvodich PF, Hansen JB, Andersson U, Sävendahl L, Hagelberg S.Etanercept treatment improves longitudinal growth in prepubertal childrenwith juvenile idiopathic arthritis.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
